Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ICT-140
- Development stage
- Discontinued
- Lead developer
- Precision Life Sciences Group
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Parenteral (likely Intradermal Or Subcutaneous)
01
Overview
ICT-140 is a patient-specific, multivalent dendritic cell-based vaccine designed for the treatment of ovarian cancer. It works by stimulating cytotoxic T lymphocyte responses against seven tumor-associated antigens that are over-expressed in ovarian cancer cells, including antigens such as EphA2, mesothelin, Her-2/neu, IL-13Rα2, and others. The underlying strategy is to induce the immune system to recognize and destroy both ovarian cancer stem cells and differentiated cancer cells. ICT-140 was developed by ImmunoCellular Therapeutics and was in preclinical or early clinical development as of late 2024. The product is classified as a cancer vaccine and specifically as a dendritic cell vaccine[1][3][5][7][9][12][15].
- Other names
- ICT 140ICT140ICT-140
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)IL13RA2 (Interleukin-13 receptor subunit alpha 2)
Beyond the preview
Go deeper on ICT-140.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ICT-140.